PDK1 decreases TACE-mediated α-secretase activity and promotes disease progression in prion and Alzheimer's diseases. - Wikidata - wikimedia - TriplyDB

PDK1 decreases TACE-mediated α-secretase activity and promotes disease progression in prion and Alzheimer's diseases.

PDK1 decreases TACE-mediated α-secretase activity and promotes disease progression in prion and Alzheimer's diseases.

http://www.wikidata.org/entity/Q47753241

about

Hijacking PrP(c)-dependent signal transduction: when prions impair Aβ clearance Differential levels of p75NTR ectodomain in CSF and blood in patients with Alzheimer's disease: a novel diagnostic marker Activation of pro-survival CaMK4β/CREB and pro-death MST1 signaling at early and late times during a mouse model of prion disease.Structure-based drug design identifies polythiophenes as antiprion compounds.The role of the NADPH oxidase NOX2 in prion pathogenesis.Parallel age-associated changes in brain and plasma neuronal pentraxin receptor levels in a transgenic APP/PS1 rat model of Alzheimer's disease.Prion infections and anti-PrP antibodies trigger converging neurotoxic pathways.Double-Edge Sword of Sustained ROCK Activation in Prion Diseases through Neuritogenesis Defects and Prion Accumulation p75NTR ectodomain is a physiological neuroprotective molecule against amyloid-beta toxicity in the brain of Alzheimer's disease Taking advantage of physiological proteolytic processing of the prion protein for a therapeutic perspective in prion and Alzheimer diseases.Clearance of amyloid-beta in Alzheimer's disease: shifting the action site from center to periphery.Regulation of PrP(C) signaling and processing by dimerization.Olfactory bulb neuroproteomics reveals a chronological perturbation of survival routes and a disruption of prohibitin complex during Alzheimer's disease progression Identification of key genes and pathways in Parkinson's disease through integrated analysis.Protective role of cellular prion protein against TNFα-mediated inflammation through TACE α-secretase.Kinase targets in CNS drug discovery.Cerebellar compartmentation of prion pathogenesis.Insights from Therapeutic Studies for PrP Prion Disease.Developing Therapeutics for PrP Prion Diseases.Increased Systemic and Plaque Inflammation in ABCA1 Mutation Carriers With Attenuation by Statins.Phosphoinositide-dependent protein kinase 1 (PDK1) mediates potent inhibitory effects on eosinophils.The transcription factor XBP1 in memory and cognition: Implications in Alzheimer disease.Targeting PDK1 for Chemosensitization of Cancer Cells.Neurodegenerative diseases: New kinase targets for Alzheimer's disease.Conditional Deletion of PDK1 in the Forebrain Causes Neuron Loss and Increased Apoptosis during Cortical Development.Regulation of RhoA GTPase and novel target proteins for ROCK.Reducing the Levels of Akt Activation by PDK1 Knock-in Mutation Protects Neuronal Cultures against Synthetic Amyloid-Beta Peptides.Role of Adipose Tissue Endothelial ADAM17 in Age-Related Coronary Microvascular Dysfunction.Alzheimer's and prion diseases: PDK1 at the crossroads.[From prion diseases to Alzheimer's disease: a common therapeutic target, PDK1].Prions activate a p38 MAPK synaptotoxic signaling pathway

P2860

Q27009790-3F72998B-09A7-4354-8982-870980B5534B Q27339637-F7C39D3D-1208-481A-ABD3-A788B1433DB4 Q34207678-DB6FE577-3BFB-4F84-99B4-49E0CF71C17E Q34488418-8CEFEB3E-89AB-41A5-98DE-36E455F0B2EF Q34682177-B6461D69-3751-43AB-A388-846E6A993DF3 Q35071220-A6539722-FA1D-4F2E-959C-9F60381773B7 Q35566835-9B7F0F97-C5F4-4D0A-A2A0-7267ACD47EDF Q35737668-5BA73B3A-8227-4005-B1ED-DD26F4961953 Q36594558-BEEA5B84-CEA7-444E-A1A0-10603081B611 Q38171006-A2C255F6-007A-4E71-8760-8B2512EF16FD Q38204711-5A4AEF1E-498A-4DA5-BECE-F040FC33423F Q38264472-1062C5A9-BAE3-4BD8-9572-EC22C06FB442 Q38287457-A066FBA3-6664-41F5-8A3C-0621898B6646 Q38430423-B49F93E8-3C7F-43FB-84FF-D9D76121C215 Q38631578-F9D1A478-6CB8-42FA-828A-D46FA2315790 Q38760031-CF58EB81-1937-43F9-9C7A-28E29D36FEEB Q38924501-BE077E75-6BB6-49F9-85B2-1F9752642683 Q39005891-99D63DA1-179E-4B5D-B073-54B60DF3E556 Q39092621-F3495643-E57A-4F7B-B371-D8530E2E9CCA Q40798941-200CD3D0-94F0-401E-B64D-CA704BBBFCC9 Q41489017-36C26453-4EA9-4935-B202-71973F510C3E Q41828232-752B20A9-1650-476B-B651-93693E24B891 Q43276810-486BA23E-521A-41D2-A318-112DDF765D13 Q44600711-D3AD52E4-7870-4BA1-8CD4-CF1547D3A18C Q47162768-BF8B1272-240F-4DD1-A628-14CFDEC1BC37 Q47336647-D1BB79C4-FAB4-4958-879E-DFA640087009 Q47845996-AD086262-6753-489C-9B29-7C1C4D0AB6C4 Q51019508-464A1D93-6BD2-409A-8CDE-29BFE77928B8 Q53343627-39B268F9-B2AE-4D27-AC40-4DB993FF67D3 Q53349598-CCB24E0C-CB9B-4C55-B9D6-C95C556FAFC3 Q58712857-ABAFE3F4-3BCB-40A9-81EC-37D279D9200A

P2860

PDK1 decreases TACE-mediated α-secretase activity and promotes disease progression in prion and Alzheimer's diseases.

http://www.wikidata.org/entity/Q47753241

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

PDK1 decreases TACE-mediated α ...... rion and Alzheimer's diseases.

@en

PDK1 decreases TACE-mediated α ...... rion and Alzheimer's diseases.

@nl

type

label

PDK1 decreases TACE-mediated α ...... rion and Alzheimer's diseases.

@en

PDK1 decreases TACE-mediated α ...... rion and Alzheimer's diseases.

@nl

prefLabel

PDK1 decreases TACE-mediated α ...... rion and Alzheimer's diseases.

@en

PDK1 decreases TACE-mediated α ...... rion and Alzheimer's diseases.

@nl

P1433

Q47753241-46FB6EC3-41B4-49A6-ACD7-477005FF92A7

P1476

Q47753241-43AA5EAC-B35C-4D83-84D6-706B70842D40

P2093

Q47753241-140FF51C-F3AC-4D62-A714-7F79F6724921

Q47753241-26A94E00-485F-4792-95F7-F97B464F6C41

Q47753241-28D22127-D6A4-4A3F-B088-30289F2C8BB3

Q47753241-3246DE2D-9EF7-40D9-97C4-7FD6000F36B8

Q47753241-381303E3-9754-4EC2-961F-82A99F127BCE

Q47753241-794E7F8C-0B5E-4338-8EC2-57B551B34B32

Q47753241-8034CE76-FE70-48FB-9042-BB406E80B36F

Q47753241-875728EB-A4EF-4D45-9384-B6A5C67AAF99

Q47753241-99E738A2-7227-411F-8835-35A1DC636568

Q47753241-C9621F1F-6337-4F82-8733-0AC28F7FC577

P2860

Q47753241-01135875-0314-4FE4-BAA3-992547AAD2F9

Q47753241-07650339-1F5B-479E-8512-DCE3F0488FD0

Q47753241-0A736EEF-BA42-4099-A301-0667CE3329B0

Q47753241-0ABE0F46-484F-4F0B-8FE0-B6F262A5F5AB

Q47753241-0E2373C2-DA27-4CAB-ACD8-90855C87EB7F

Q47753241-177E2363-2127-4354-9BA8-394415B89724

Q47753241-17B47FEC-0935-4207-B738-882AD9B453EC

Q47753241-1D7C6004-44F8-4390-BF9F-FDE91A95AA49

Q47753241-240D8235-2203-4E02-8728-F9446C724650

Q47753241-243831B8-91A5-481A-A537-42188EDE3466

P2888

Q47753241-616278CD-B311-440D-85A5-D6AEE0136602

P304

Q47753241-E7FA2A98-9CCB-4276-9469-6BCB333A29DE

P31

Q47753241-0A7847C7-7740-469B-93E4-64B3CB639A30

P356

Q47753241-4A0242A6-BBF6-4E12-8F34-AA4D81132669

P407

Q47753241-E035D889-C042-4BAB-83D0-FAB346FF1E89

P433

Q47753241-55EA4ADC-6D63-4E0B-BFA4-09256A806830

P478

Q47753241-9CF87106-9701-4F86-8B0D-076419E393BB

P50

Q47753241-6384F8CE-8FE0-4F0A-BBF0-9C908B80B2FB

P577

Q47753241-265105C5-A153-4CED-A5FF-AD81467B5EEF

P5875

Q47753241-5C01D167-BD9E-49E3-9276-73EF1F1BCD93

P698

Q47753241-D8190785-632C-46E2-92FC-95412B28A2AD

P921

Q47753241-938228F7-0A8D-4A13-82A9-BBB79FFFB831

Q47753241-FF17C502-68D7-4349-B948-42DA93AE0DAC

P356

P1433

Nature Medicine

P1476

PDK1 decreases TACE-mediated α ...... rion and Alzheimer's diseases.

@en

P2093

Audrey Ragagnin

http://www.w3.org/2001/XMLSchema#string

Aurélie Alleaume-Butaux

http://www.w3.org/2001/XMLSchema#string

Benoit Schneider

http://www.w3.org/2001/XMLSchema#string

Caroline Dakowski

http://www.w3.org/2001/XMLSchema#string

Jean-Marie Launay

http://www.w3.org/2001/XMLSchema#string

Julia Hernandez-Rapp

http://www.w3.org/2001/XMLSchema#string

Mathéa Pietri

http://www.w3.org/2001/XMLSchema#string

Odile Kellermann

http://www.w3.org/2001/XMLSchema#string

Samia Hannaoui

http://www.w3.org/2001/XMLSchema#string

Sophie Mouillet-Richard

http://www.w3.org/2001/XMLSchema#string

P2860

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers

ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models

Immuno-localization of the insulin regulatable glucose transporter in brown adipose tissue of the rat

Small-animal PET imaging of amyloid-beta plaques with [11C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Proteolytic processing of Alzheimer's β-amyloid precursor protein

The prion's elusive reason for being

The ADAM metalloproteinases

miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants

P2888

P304

1124-1131

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.3302

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Michel Peyrin

P577

2013-08-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255976159

http://www.w3.org/2001/XMLSchema#string

P698

23955714

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

Prion protein family